These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 3107222)
1. Acceptability of cell substrates for production of biologicals. Report of a WHO Study Group on Biologicals. World Health Organ Tech Rep Ser; 1987; 747():1-29. PubMed ID: 3107222 [No Abstract] [Full Text] [Related]
2. Evaluation of cell substrates for the production of biologicals: Revision of WHO recommendations. Report of the WHO Study Group on Cell Substrates for the Production of Biologicals, 22-23 April 2009, Bethesda, USA. Knezevic I; Stacey G; Petricciani J; Sheets R; Biologicals; 2010 Jan; 38(1):162-9. PubMed ID: 19818645 [TBL] [Abstract][Full Text] [Related]
3. WHO requirements for the use of animal cells as in vitro substrates for the production of biologicals (requirements for biological substances No 50). Dev Biol Stand; 1998; 93():141-71. PubMed ID: 9737395 [No Abstract] [Full Text] [Related]
4. Regulatory philosophy and acceptability of cells for the production of biologicals. Petricciani JC Dev Biol Stand; 1991; 75():9-15. PubMed ID: 1794634 [TBL] [Abstract][Full Text] [Related]
5. Status of WHO concerning continuous cell lines as substrates for the production of biologicals. Grachev V; Magrath D Dev Biol Stand; 1989; 70():215-9. PubMed ID: 2759349 [No Abstract] [Full Text] [Related]
6. WHO requirements for the use of animal cells as in vitro substrates for the production of biologicals (Requirements for biological susbstances no. 50). Grachev V; Magrath D; Griffiths E Biologicals; 1998 Sep; 26(3):175-93. PubMed ID: 10208720 [No Abstract] [Full Text] [Related]
7. Viral safety of biological products in WHO policy. Grachev VP Dev Biol Stand; 1991; 75():241-6. PubMed ID: 1794628 [TBL] [Abstract][Full Text] [Related]
8. Safety issues relating to the use of mammalian cells as hosts. Petricciani JC Dev Biol Stand; 1985; 59():149-53. PubMed ID: 3891461 [TBL] [Abstract][Full Text] [Related]
9. WHO requirements for the use of animal cells as in vitro substrates for the production of biologicals: application to influenza vaccine production. Griffiths E Dev Biol Stand; 1999; 98():153-7; discussion 167. PubMed ID: 10494968 [No Abstract] [Full Text] [Related]
11. Industry perspective for biotech products. Möritz A Dev Biol (Basel); 2004; 118():37-44. PubMed ID: 15645671 [TBL] [Abstract][Full Text] [Related]
12. Cell line issues: historical and future perspectives. Petricciani JC Dev Biol Stand; 1992; 76():5-11. PubMed ID: 1478355 [TBL] [Abstract][Full Text] [Related]
13. WHO Expert Committee On Biological Standardization. World Health Organ Tech Rep Ser; 1998; 878():i-vi, 1-101. PubMed ID: 9731464 [TBL] [Abstract][Full Text] [Related]
14. The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals. Farshid M; Taffs RE; Scott D; Asher DM; Brorson K Curr Opin Biotechnol; 2005 Oct; 16(5):561-7. PubMed ID: 16095899 [TBL] [Abstract][Full Text] [Related]
15. Risk assessment on the carcinogenic potential of hybridoma cell DNA: implications for residual contaminating cellular DNA in biological products. Dortant PM; Claassen IJ; van Kreyl CF; van Steenis G; Wester PW Biologicals; 1997 Dec; 25(4):381-90. PubMed ID: 9467034 [TBL] [Abstract][Full Text] [Related]
16. WHO Expert Committee on biological standardization. World Health Organ Tech Rep Ser; 2007; (941):1-340, back cover. PubMed ID: 18314862 [TBL] [Abstract][Full Text] [Related]
17. Continuous cell lines as substrates for biologicals: report of a joint meeting of WHO, IABS (cell Culture Committee Subsection), and ESACT. Spier RE Mol Biother; 1988; 1(2):114-5. PubMed ID: 3269249 [No Abstract] [Full Text] [Related]
18. Continuous cell lines as substrates for biologicals. Draft position paper. Pharmaceutical Manufacturer's Association. Dev Biol Stand; 1989; 70():285-7. PubMed ID: 2759355 [No Abstract] [Full Text] [Related]
19. Experience in cell line testing. Moore WA Dev Biol Stand; 1992; 76():51-6. PubMed ID: 1478356 [TBL] [Abstract][Full Text] [Related]
20. Viral safety and clearance evaluation--implications for process change and comparability. Dinowitz M Dev Biol (Basel); 2002; 109():121-6. PubMed ID: 12434921 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]